Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554898 | 1.00 | RAB9A (0.72) | RAB9ALMNAKMT2AMEN1POLB | |
| SCHEMBL192930 | 0.87 | ALDH1A1 (0.69) | RAB9ALMNAPOLBPTPN1ALDH1A1 | |
| SCHEMBL27124630 | 0.86 | TP53 (0.57) | RAB9ALMNAPOLBTP53PTPN1 | |
| SCHEMBL26986504 | 0.86 | TP53 (0.57) | RAB9ALMNAPOLBTP53PTPN1 | |
| SCHEMBL27136774 | 0.86 | RAB9A (0.55) | RAB9ALMNAKMT2AMEN1POLB | |
| SCHEMBL26986347 | 0.86 | RAB9A (0.55) | RAB9ALMNAKMT2AMEN1POLB | |
| SCHEMBL7978728 | 0.83 | RAB9A (0.52) | RAB9ALMNAKMT2AMEN1POLB | |
| SCHEMBL28589349 | 0.83 | RAB9A (0.61) | RAB9ALMNAKMT2APOLBALDH1A1 | |
| SCHEMBL28589348 | 0.83 | RAB9A (0.61) | RAB9ALMNAKMT2APOLBALDH1A1 | |
| SCHEMBL23390168 | 0.83 | EPHX2 (0.60) | RAB9ALMNAPOLBTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM1 | RAB9A 1437/4885LMNA 4649/4885KMT2A 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.